Encorium Group, Inc. Announces $3.8 Million Contract For Phase 2 Clinical Trial in Herpes Zoster (Shingles)

WAYNE, Pa.--(BUSINESS WIRE)--Encorium Group, Inc. (Nasdaq: ENCO), a leader in the design, development, and management of complex clinical trials and patient registries for many of the world's leading pharmaceutical and biotechnology companies, today announced the signing of a $3.8 million contract for a Phase 2 clinical trial of a new antiviral agent to treat herpes zoster (shingles). Encorium will provide multiple services including program consulting, project management, site management and monitoring, data management, biostatistical support, and medical writing. Revenue recognition will begin during the current second quarter and continue on a proportional performance basis over the life of the contract as services are performed.